BANGALORE, India--(BUSINESS WIRE)--Avesthagen announced today its plans to enter the US market with its line of proprietary medicinal extracts. The company, based in India, has a systematic approach for developing stable and reliable extracts from plants used in traditional herbal medicine in Asia. The Avesthagen system applies scientific principles utilized in drug development to discover products with clinically-proven efficacy for specific health conditions. Avesthagen manufactures its proprietary extracts for functional food manufacturers and dietary supplement marketing companies. The company already collaborates with a number of world-class pharmaceutical and food manufacturers based outside of the US, such as Nestle, Danone, Novartis and AstraZeneca. Avesthagen is now seeking North American partners for the development of new extracts or to market those already available.
Avesthagen currently has medicinal extracts with strong efficacy in two health conditions of particular concern in North America: Type 2 diabetes and bone health. The company has discovered several extracts that improve the glycemic index of foods. Reducing the glycemic index reduces insulin demand and it is widely believed that this can delay the onset of Type 2 diabetes and assist in the management of the condition once established. The extracts perform as well as leading drugs sold for the same purpose.
The Avesthagen bone health product shows promise for arresting the loss of bone density, a pronounced problem in mature women, and, unlike most remedies, has been shown to actually rebuild bone density. This product could be incorporated in foods in the same manner that calcium is now added for this purpose, or taken as a supplement.
Avesthagen was founded in 1998 by one of India's pioneers and leading biotech entrepreneurs Dr. Villoo Morawala-Patell, who got her Ph.D. from Louis Pasteur University in Strasbourg, France, in 1993. It began business operations officially in 2001.
Since its inception Avesthagen has grown into one of India's leading healthcare technology groups in India, and its activities include, in addition to its agri-biotechnologies product pipeline, development of scientifically validated bioactive nutraceuticals, derived from Indian medicinal plants, as well as the development of a pipeline of bio-similar drugs. Avesthagen has four strategic business units: Biopharmaceuticals, Food For Medicine (Nutraceuticals), Seed For Food (agribiotech) and Science Innovation. Avesthagen's partners include multiple top 10 global companies in each of its fields of research.
Avesthagen collaborates at every stage in the value chain with appropriate partners, both public and private, for access to and exchange of technology and overall commercial expertise to leverage the 'India advantage'. Avesthagen employs 250 people worldwide. For Avesthagen on the web: www.avesthagen.com.